Drug intelligence / Profile preview

SGA300A

Development stage: Preclinical
Lead developer: BMG Pharma
Administration: Intradermal

Overview

SGA300A is an injectable superficial skin booster currently in preclinical development by BMG Pharma for applications in aesthetic medicine. Designed as a "superficial booster," it is intended for injection into the upper layers of the dermis to improve skin quality, hydration, and texture. The product is part of BMG Pharma's pipeline of aesthetic solutions, which typically leverage specialized hyaluronic acid-based technologies to provide targeted skin revitalization and rejuvenation.

Brand names: SGA300A Booster SuperficialSGA-300A Booster SuperficialSGA 300A Booster Superficial
Other names: SGA300A Booster SuperficialSGA-300A Booster SuperficialSGA 300A Booster Superficial

Beyond the preview

Go deeper on SGA300A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SGA300A.

Explore the full profile